FAST-MAS: CERC-501 for Anhedonia in Mood and Anxiety Disorders

Phase 2, randomised, double-blind trial in major depressive disorder (MDD), bipolar disorder (BD), generalized anxiety disorder (GAD) and 3 more comparing CERC-501 with Placebo (2 arms). Primary endpoint: Change in Ventral Striatal Activation Occurring in Anticipation of Reward During the Monetary Incentive Delay Task Measured by fMRI at Week 8. Started Jun 2015; status: completed.